<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82427">
  <stage>Registered</stage>
  <submitdate>13/02/2008</submitdate>
  <approvaldate>20/02/2008</approvaldate>
  <actrnumber>ACTRN12608000096358</actrnumber>
  <trial_identification>
    <studytitle>A double blind, randomised, placebo-controlled, mulitcentre study to assess the efficacy and safety of adjunctive zonisamide in primary generalised tonic clonic seizures.</studytitle>
    <scientifictitle>Efficacy and safety of adjuntice zonisamide in primary generalised tonic clonic seizures</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>E2090- E044-315</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>epilepsy</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Epilepsy</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>adjunctive therapy - Zonisamide. Patients will take study drug (either Zonisamide or placebo) alongside their usual Antiepileptic drug's. Patient's will commence on a dose of 1mg/kg (subjects&lt;12 years or 50mg (subjects &gt;12 years). Further dose increases will occur at one week intervals until a dose of 5mg/kg or 300mg is reached by week 4. Patients will then maintain their dose for futher 12 weeks.</interventions>
    <comparator>Placebo will be the comparator to Zonisamide. Placebo will be dispensed in the same way as Zonisamide.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>decrease of seizure frequency</outcome>
      <timepoint>after 16 weeks of active therapy</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>safety - blood samples will be taken and assessed for safety laboratory values.</outcome>
      <timepoint>At screening and final visit (after 16 weeks of active therapy)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>primary generalized tonic clonic seizures</inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>any other type of epilepsy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Subjects will be enrolled and allocated to a treatment using a central randomisation system by phone.</concealment>
    <sequence>Subjects will be randomised using a central randomisation system which will determine the sequence of patients.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>20/02/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>154</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Terminated</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3050,</postcode>
    <postcode>3084</postcode>
    <postcode>2031</postcode>
    <postcode>2067</postcode>
    <postcode>3065</postcode>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lithuania</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Serbia and Montenegro</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Croatia</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Eisia G.C.D., Eisai Ltd.</primarysponsorname>
    <primarysponsoraddress>3 Shortlands, London, W6 8EE, UK</primarysponsoraddress>
    <primarysponsorcountry>United Kingdom</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Eisai Global Clinical Development, Eisia Ltd.</fundingname>
      <fundingaddress>3 Shortlands, London. W6 8EE, UK</fundingaddress>
      <fundingcountry>United Kingdom</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Parexel International Limited</sponsorname>
      <sponsoraddress>The Quays
101-105 Oxford Road, Uxbridge, Middlesex, UB8 1LZ</sponsoraddress>
      <sponsorcountry>United Kingdom</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Parexel International Limited</sponsorname>
      <sponsoraddress>3 Thomas Holt Drive
North Ryde
NSW 2113</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is designed to compare how safe and effective zonisamide is compared to placebo in people with primary generalised tonic clonic seizures who are already being treated with one or two other anti-epileptic drugs. Zonisamide is an investigational drug.
Primary Research Objective:  To assess the efficacy of adjunctive zonisamide in IGE in reducing the frequency of tonic-clonic seizures in subjects with continuing continuing primary generalised tonic-clonic seizures
Secondary Research Objective:  To assess the safety and tolerability of adjunctive zonisamide.
Exploratory Research Objective: To further explore the efficacy of zonisamide on other seizure types expected to occur in a significant proportion of subjects (myoclonic seizures, absence seizures).
This is a double-blind, randomised, placebo-controlled study comparing zonisamide and placebo in 154 subjects (1:1 ratio). The study consists of Baseline, Titration and Maintenance periods.

Baseline Period - once the Screening Visit has been performed, a seizure diary will be maintained to document the baseline seizure frequency in the eight weeks before the Randomisation Visit.

Titration Period - zonisamide/placebo dose will commence at 1 mg/kg in subjects &lt;12 years of age or at 50 mg for subjects 12 years of age. Further dose increases will occur at one week intervals until at dose of 5 mg/kg or 300 mg is reached by Week 4. If adverse events (AEs) occur, one titration step will be omitted during Weeks 0-3, in which case the dose reached at Week 4 will be 4 mg/kg or 250 mg. Subject's who require further down titration will be withdrawn from the study.

Maintenance Period - subjects will be treated with their Week 4 dose. In the event of seizures occurring in the first two weeks of the Maintenance Period, the dose will be increased to 6 mg/kg or 400 mg (or 5 mg/kg or 350 mg, if the subject omitted one dose in the Titration Period and the AE that led to this dose increase omission has subsided). The dose will be reduced to 4 mg/kg or 200 mg in dose-limiting AEs. Subjects who require further down titration or dose increases will be withdrawn (with the exception of those who had temporary dose decreases for not more that 4 days when necessitated by intercurrent illness). During the remainder of the Maintenance Period, the dose of study medication must remain unchanged.

During the entire study the patient will keep a seizure diary to ascertain seizure frequency and type. Adverse events (AEs) will be reviewed at every visit, also physical and neurological exams, orthostatic vitals, 12 lead ECGs and clinical labs will be collected at every visit.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Melbourne Human Research Ethics Committee</ethicname>
      <ethicaddress>Ward 6 East, Research Directorate
Gratten St
Parkville
VIC 3050</ethicaddress>
      <ethicapprovaldate>20/02/2008</ethicapprovaldate>
      <hrec>2007-287</hrec>
      <ethicsubmitdate>21/11/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Northern Sydney Central Coast Human Research Ethics Committee</ethicname>
      <ethicaddress>Research Office, RNSH
Level 4
Vindin House,
Pacific Highway, St Leonards
NSW 2065</ethicaddress>
      <ethicapprovaldate />
      <hrec>08/HARBR/7/8</hrec>
      <ethicsubmitdate>10/01/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Austin Health Human Research Ethics Committee</ethicname>
      <ethicaddress>Level 8, Room 8322
Harold Stokes Building
Austin Hospital
145 Studley Road
Heidelberg
Victoria
3084</ethicaddress>
      <ethicapprovaldate>4/06/2008</ethicapprovaldate>
      <hrec>H2008/03171</hrec>
      <ethicsubmitdate>16/01/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincents Hospital (melbourne) Human Research Ethics Committee</ethicname>
      <ethicaddress>Level 5, Aikenhead Building
27 Victoria Parade
Fitzroy 
VIC 3065</ethicaddress>
      <ethicapprovaldate />
      <hrec>014/08</hrec>
      <ethicsubmitdate>31/01/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Janos Antal M.D.</name>
      <address>Hermina utca 17.
Budapest, H-1146</address>
      <phone>36 1 461-7600</phone>
      <fax />
      <email>janos.antal@parexel.com</email>
      <country>Hungary</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sophie Nzongani-Morin</name>
      <address>190 Rue Championnet
PARIS,  75018</address>
      <phone>+33 1 44 90-32 31</phone>
      <fax />
      <email>Sophie.Nzongani-Morin@parexel.com</email>
      <country>France</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Sophie Nzongani-Morin</name>
      <address>190 Rue Championnet
PARIS,  75018</address>
      <phone>+33 1 44 90-32 31</phone>
      <fax />
      <email>Sophie.Nzongani-Morin@parexel.com</email>
      <country>France</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>